A postdoctoral position is available immediately for a neuropharmacologist at the University of Utah in the laboratory of Dr. J. Michael McIntosh. The candidate will develop preclinical compounds for treating neuropathic pain and evaluate related molecular mechanisms.
The candidate will have the opportunity to integrate molecular, biochemical, and genetic approaches in ongoing multidisciplinary projects to study mechanisms of pain and neuropathy. The research will involve a variety of techniques including electrophysiological recording, pharmacological testing and calcium imaging. The candidate will join a multidisciplinary group of investigators with funding from NIH and the Department of Defense. This position will have the possibility of collaborating scientifically with a team of PIs in Biology, Medicinal Chemistry and Psychiatry.
See for example:
Romero HK, Christensen SB, Di Cesare Mannelli L, Gajewiak J, Ramachandra R, Elmslie KS, Vetter DE, Ghelardini C, Iadonato SP, Mercado JL, Olivera BM, McIntosh JM. Inhibition of alpha9alpha10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain. Proc Natl Acad Sci U S A. 2017;114(10):E1825-E32.
Interested individuals are encouraged to forward a brief letter of interest, curriculum vitae, a list of three references and career goals combined into 1 pdf file to email@example.com and firstname.lastname@example.org.
A Ph.D. and experience in neuropharmacology or basic neuroscience are essential. Experience in electrophysiology is required. Experience in rodent operant behavior is preferred. The candidate will be provided with significant training in those disciplines with which they are less familiar, as well as mentoring to facilitate the transition to an independent research career.
The University of Utah, located in Salt Lake City in the foothills of the Wasatch Mountains, is the flagship institution of higher learning in Utah. Founded in 1850, it serves more than 32,000 students from across the U.S. and the world.